Compare Abeona Therapeutics Inc (ABEO) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Roundhill NVDA WeeklyPay ETF trades at $38.32. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | NVDW | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.45 | $52.59 |
52-Week Low | $4.17 | $31.88 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
NVDW, trading at $38.53, gained 3.21% in the last session with a bullish technical signal driven by moving averages. The stock exhibits strong weekly dividend activity, with recent payouts ranging from $0.13 to $0.48, indicating a focus on income generation. Key resistance lies near $39, while support is established around $36–37.
The outlook hinges on NVDW's ability to sustain its dividend strategy amid market volatility. Risks include payout consistency and reliance on underlying asset performance. Opportunities exist for income-focused investors, but cautious monitoring of technical overbought signals is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
